SCHEMBL1198552

SCHEMBL1198552

Cc1cc(C(=O)O)n(Cc2nc(-c3cccc(C(F)(F)F)c3)cs2)n1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.51
KDM4E B2RXH2 1/20 0.51
MEN1 O00255 1/20 0.51
KMT2A Q03164 1/20 0.51
PTGER1 P34995 1/20 0.48
CFTR P13569 2/20 0.48
SMN1; SMN2 Q16637 2/20 0.43
KMO O15229 2/20 0.43
LMNA P02545 2/20 0.43
CASP3 P42574 1/20 0.43
HTT P42858 1/20 0.43
SENP8 Q96LD8 1/20 0.43
SENP7 Q9BQF6 1/20 0.43
SENP6 Q9GZR1 1/20 0.43
ITGB2 P05107 1/20 0.43
ICAM1 P05362 1/20 0.43
ITGAL P20701 1/20 0.43
ADORA2A P29274 1/20 0.43
SIRT5 Q9NXA8 1/20 0.42
TRPA1 O75762 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1197814 0.89 MEN1 (0.48) ALDH1A1KDM4EMEN1KMT2APTGER1
SCHEMBL1199380 0.84 PTGER1 (0.52) ALDH1A1KDM4EMEN1KMT2APTGER1
SCHEMBL1197463 0.82 ITGB2 (0.52) ALDH1A1KDM4EMEN1KMT2APTGER1
SCHEMBL1198442 0.78 KDM4E (0.56) ALDH1A1KDM4EMEN1KMT2ACFTR
SCHEMBL12890153 0.78 AR (0.42) ALDH1A1KDM4EMEN1KMT2APTGER1
SCHEMBL3077688 0.78 P2RY14 (0.54) PTGER1LMNAHTTALPLRECQL
SCHEMBL1198444 0.77 MAPT (0.48) ALDH1A1KDM4EMEN1KMT2APTGER1
SCHEMBL1198946 0.77 KDM4E (0.47) ALDH1A1KDM4EMEN1KMT2APTGER1
SCHEMBL1198334 0.75 MEN1 (0.60) ALDH1A1KDM4EMEN1KMT2APTGER1
SCHEMBL1198344 0.75 KDM4E (0.47) ALDH1A1KDM4EMEN1KMT2APTGER1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8461348-B2 Heterocyclic derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-06-11 US disclosed
US-8461348-B2 Heterocyclic derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-06-11 US disclosed
US-20110028493-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-02-03 US disclosed
US-20110028493-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-02-03 US disclosed
EP-2264017-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2010-12-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110028493-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF PDE3B, PDE5A, PDE2A ALDH1A1 1037/4885KDM4E 1877/4885MEN1 2661/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.